Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Roivant Sciences Ltd (NASDAQ: ROIV) was $14.41 for the day, up 4.65% from the previous closing price of $13.77. In other words, the price has increased by $4.65 from its previous closing price. On the day, 15.25 million shares were traded. ROIV stock price reached its highest trading level at $14.475 during the session, while it also had its lowest trading level at $13.82.
Ratios:
Our analysis of ROIV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 40.54 and its Current Ratio is at 40.54. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on September 02, 2025, initiated with a Buy rating and assigned the stock a target price of $16.
On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $17.Wolfe Research initiated its Outperform rating on February 15, 2024, with a $17 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 03 ’25 when Ramaswamy Vivek sold 1,195,000 shares for $12.50 per share. The transaction valued at 14,937,500 led to the insider holds 36,089,108 shares of the business.
Ramaswamy Vivek sold 385,816 shares of ROIV for $5,000,175 on Sep 05 ’25. The 10% Owner now owns 35,508,359 shares after completing the transaction at $12.96 per share. On Sep 04 ’25, another insider, Ramaswamy Vivek, who serves as the 10% Owner of the company, sold 194,933 shares for $12.92 each. As a result, the insider received 2,518,534 and left with 35,894,175 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ROIV now has a Market Capitalization of 9840329728 and an Enterprise Value of 5907141120. For the stock, the TTM Price-to-Sale (P/S) ratio is 423.60 while its Price-to-Book (P/B) ratio in mrq is 2.26. Its current Enterprise Value per Revenue stands at 254.256 whereas that against EBITDA is -5.144.
Stock Price History:
The Beta on a monthly basis for ROIV is 1.15, which has changed by 0.2068677 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, ROIV has reached a high of $13.82, while it has fallen to a 52-week low of $8.73. The 50-Day Moving Average of the stock is 22.33%, while the 200-Day Moving Average is calculated to be 28.26%.
Shares Statistics:
ROIV traded an average of 6.10M shares per day over the past three months and 8809910 shares per day over the past ten days. A total of 682.23M shares are outstanding, with a floating share count of 431.75M. Insiders hold about 36.78% of the company’s shares, while institutions hold 64.12% stake in the company. Shares short for ROIV as of 1756425600 were 39048414 with a Short Ratio of 6.40, compared to 1753920000 on 38312269. Therefore, it implies a Short% of Shares Outstanding of 39048414 and a Short% of Float of 7.670000000000001.
Earnings Estimates
A comprehensive evaluation of Roivant Sciences Ltd (ROIV) is underway, with the input of 4.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.25 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$0.95 and -$1.56 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$1.37, with 5.0 analysts recommending between -$1.18 and -$1.82.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $15M to a low estimate of $1.78M. As of the current estimate, Roivant Sciences Ltd’s year-ago sales were $29.26MFor the next quarter, 6 analysts are estimating revenue of $7.45M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $1.78M.
A total of 10 analysts have provided revenue estimates for ROIV’s current fiscal year. The highest revenue estimate was $47.2M, while the lowest revenue estimate was $2.17M, resulting in an average revenue estimate of $21.25M. In the same quarter a year ago, actual revenue was $29.05MBased on 9 analysts’ estimates, the company’s revenue will be $30.36M in the next fiscal year. The high estimate is $99.5M and the low estimate is $2.24M.
